TransCode Therapeutics Publishes Study on Lead Candidate's Preclinical Efficacy Against Metastatic Cancer

TransCode Therapeutics, Inc., an RNA oncology company listed on NASDAQ under the ticker RNAZ, has announced promising results from a study involving its lead therapeutic candidate, TTX-MC138. The study, conducted in collaboration with Michigan State University, was published in the journal Oncotarget on August 26, 2024. It was led by Dr. Anna Moore, a Professor and Director of the Precision Health Program at Michigan State University, who is also a scientific co-founder of TransCode.

The research highlights the role of TTX-MC138 in reducing the self-renewal capacity of tumor cells, specifically targeting stem-like breast cancer cells that are known to express higher levels of miR-10b. This molecule, miR-10b, is the primary target of TTX-MC138. The findings suggest that treatment with TTX-MC138 lowers the stemness of breast cancer cells, which is crucial because these properties enable metastatic cells to proliferate and spread.

Cancer stemness refers to the ability of certain cancer cells to self-renew and adapt to new environments, traits that are essential for metastasis and tumor formation in new organs. These cancer stem cells possess developmental plasticity, making them uniquely capable of initiating new tumors and driving metastatic disease.

Dr. Zdravka Medarova, Chief Scientific Officer of TransCode and co-author of the publication, commented on the significance of these findings. She emphasized that understanding the mechanisms behind TTX-MC138's impact on metastatic cancer is vital as the company progresses with its Phase 1 clinical trial. Dr. Medarova noted that this knowledge could enhance predictions of clinical responses in individual patients based on the specific molecular characteristics of their cancers. Additionally, these insights may help identify molecular biomarkers that can serve as early indicators of therapeutic efficacy and aid in better patient stratification for future clinical trials.

TransCode Therapeutics is dedicated to addressing metastatic disease through the innovative design and delivery of RNA therapeutics, utilizing its proprietary TTX nanoparticle platform. The company's primary focus is on TTX-MC138, which targets metastatic tumors that overexpress microRNA-10b—a well-documented marker of metastasis. Beyond TTX-MC138, TransCode is also developing a range of first-in-class RNA therapeutic candidates aimed at overcoming the challenges associated with RNA delivery, thus opening up new avenues for targeting novel genetic factors relevant to various types of cancer.

By unveiling these results, TransCode Therapeutics underscores its commitment to advancing cancer treatment through cutting-edge RNA-based solutions, offering new hope in the fight against metastatic disease.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!